Home/Pipeline/DB-001

DB-001

Solid Tumors

Phase 1Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Active

Company

Dren Bio

About Dren Bio

Dren Bio is a South San Francisco-based biotech founded in 2019, advancing a pipeline of first-in-class antibody therapeutics. The company's core approach involves engineering antibodies to selectively engage immune effector cells, like macrophages, to phagocytose and clear pathological targets. With two clinical-stage programs and a broader preclinical portfolio in oncology, immunology, and neurology, Dren aims to address significant unmet medical needs through its novel depletion mechanisms. As a private, pre-revenue company, its success hinges on clinical validation of its proprietary platforms.

View full company profile

Therapeutic Areas

Oncology Autoimmune Neurology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed